This HTML5 document contains 149 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n8http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q53127020
rdf:type
wikibase:Item
schema:description
artículu científicu wissenschaftlicher Artikel 2012年学术文章 artikulong pang-agham tudományos cikk scientific article published on 16 July 2012 article scientific 2012年學術文章 videnskabelig artikel articolo scientifico 2012年学术文章 บทความทางวิทยาศาสตร์ 2012 nî lūn-bûn article científic научни чланак tieteellinen artikkeli artykuł naukowy 2012年学术文章 2012年學術文章 2012年の論文 vetenskaplig artikel artigo científico vitskapeleg artikkel 2012년 논문 artículo científico publicado en 2012 artikull shkencor 2012年学术文章 vedecký článok επιστημονικό άρθρο научная статья article scientifique wetenschappelijk artikel bài báo khoa học 2012年学术文章 artigo científico scienca artikolo מאמר מדעי vitenskapelig artikkel vědecký článek articol științific наукова стаття, опублікована в липні 2012 artigo científico 2012年學術文章 teaduslik artikkel scientific article published on 16 July 2012 scientific article published on 16 July 2012 2012年學術文章 artikel ilmiah мақолаи илмӣ 2012年學術文章 ১৬ জুলাই ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ სამეცნიერო სტატია 2012年学术文章 научни чланак مقالة علمية نشرت في 16 يوليو 2012 naučni članak научна статия bilimsel makale
p:P577
wds:Q53127020-5A579206-85EB-4949-9DCF-076E11B2BCB4
wdt:P577
2012-07-16T00:00:00Z
p:P407
wds:Q53127020-F54B83CC-4780-4512-B244-BF74A1EB7C5E
wdt:P407
wd:Q1860
p:P2093
wds:Q53127020-025263D4-3114-47B5-809A-C7AFA599731A wds:Q53127020-0B4A1294-7507-45C8-AAB3-C1928118F223 wds:Q53127020-0B691EE1-7A5D-4F99-98CE-1FD7B83809E9 wds:Q53127020-02F1E6DF-E2C4-4E7A-8ECE-828FBE53B975 wds:Q53127020-36C534A7-B87B-4F58-9D8D-2DF0358380F1 wds:Q53127020-3D0C36EA-81E5-436C-884A-E7DAA274BFFC wds:Q53127020-2FB26375-8607-42B8-B9FD-CC624D8187BA wds:Q53127020-439868AD-5676-4CB9-8CF4-4AA027BBB744 wds:Q53127020-7EAB107F-68B0-4366-A47E-BE7B70B0125D wds:Q53127020-65EA5B07-9774-4076-BE62-2C84BD5F57FB wds:Q53127020-9EC4F726-754F-4DA8-AF3E-F448CD3F7BD9 wds:Q53127020-8C888545-4DFC-4C72-9E3B-18BD65412968 wds:Q53127020-BA70645C-1754-4925-A4EA-A07A33966F61 wds:Q53127020-AEEAB103-6A14-45AB-BDE4-E4C9403A745A wds:Q53127020-CFBE4227-A0CF-4FC0-AC87-75788EC9D895 wds:Q53127020-CB4CFE91-3837-4C7F-8EEA-33892D9D4249 wds:Q53127020-CBC5346D-40D6-47E8-9774-B9980395BB1B wds:Q53127020-EE52A4F3-70CC-4E46-B4EE-C547FC1257D7 wds:Q53127020-EA5AF3D3-3195-4149-B578-C8FE33F9F526 wds:Q53127020-EC67F223-C8CF-4CA3-B435-917D9B7A9CCF wds:Q53127020-F9E05FBA-3D9B-4B8F-A839-63894476EAAC wds:Q53127020-FFB75124-A4EA-46AA-B579-98B785C12743
wdt:P2093
Walter Lindemann Helgi van der Velde Gerard M J Bos Marinus van Marwijk-Kooy Ulrich Duehrsen Laila El Jarari Marian Stevens-Kroef Katja C Weisel Shulamiet Wittebol Martijn R Schaafsma Annemiek Broyl Christof Scheid Reinier Raymakers Igor W Blau Ingo G H Schmidt-Wolf Pierre W Wijermans Anna Jauch Marie-Jose Kersten Edo Vellenga Hartmut M Goldschmidt Hans Salwender Uta Bertsch
rdfs:label
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
skos:prefLabel
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
schema:name
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
p:P50
wds:Q53127020-A9D86CEF-BE8B-4D88-A032-C901D1C7A54F wds:Q53127020-0399D5A6-CCE3-4B3A-8D3E-1D46D13EC7FE wds:Q53127020-26E5E9DB-F26B-4B97-AC0B-B14F97BED475 wds:Q53127020-9F83EC1C-A7B9-43D0-AA98-6A9549F1CB76 wds:Q53127020-4A67E23B-68EC-484C-AAD2-1D43462AF7E7 wds:Q53127020-F634866D-ABE4-4AAF-9F5C-22A4F3825661
wdt:P50
wd:Q66381326 wd:Q110192041 wd:Q110173595 wd:Q92858507 wd:Q1928879 wd:Q73546936
p:P1476
wds:Q53127020-7CCBD40F-7AF4-4147-820C-C58539CD5819
wdt:P1476
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
p:P304
wds:Q53127020-9CA64263-54FE-46E3-81B1-A394C0B4355E
wdt:P304
2946-2955
p:P31
wds:Q53127020-8BA0BDF8-548B-4960-AC19-F258F81645B2
wdt:P31
wd:Q13442814
p:P921
wds:Q53127020-F45DBAE7-8667-4A17-A367-C635186B10BE wds:Q53127020-4F10CCA5-F70E-456D-9B60-5FE602DF5741 wds:Q53127020-20F50D7A-FC1F-4148-87F3-182243F75026
wdt:P921
wd:Q42824827 wd:Q467635 wd:Q181600
p:P698
wds:Q53127020-E6317A31-635D-40A8-888F-01E43DBD479B
wdtn:P698
n9:22802322
wdt:P698
22802322
p:P1433
wds:Q53127020-3231CCA4-4A8B-43B0-8C3E-9F886495241C
wdt:P1433
wd:Q400292
p:P433
wds:Q53127020-CAE3CA87-CC36-4782-860B-A1F7998ED411
p:P478
wds:Q53127020-2D178C62-7313-4298-B3E0-5608CEF5509E
wdt:P433
24
wdt:P478
30
p:P356
wds:Q53127020-2DD14699-F5D4-402B-A5F6-0238A0083831
wdtn:P356
n8:JCO.2011.39.6820
wdt:P356
10.1200/JCO.2011.39.6820